Tango Therapeutics, Inc. Cash Flow Statement
TNGX / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Tango Therapeutics, Inc. used $139M in operating cash flow and negative free cash flow of $140M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | -$101.6M | -$130.3M | -$101.7M | -$58.2M | -$52.0M | -$52.0M |
| Depreciation & Amortization | - | - | - | $897.0K | $718.0K | $718.0K |
| Operating Cash Flow | -$138.9M | -$131.5M | -$118.0M | -$59.5M | $70.1M | $70.1M |
| Capital Expenditures | $1.0M | $754.0K | $1.5M | $1.8M | $1.1M | $1.1M |
| Free Cash Flow | -$139.9M | -$132.3M | -$119.5M | -$61.4M | $69.0M | $69.0M |
| FCF Margin | -224.3% | -314.4% | -327.2% | -165.7% | 900.8% | - |